CN103520717A - 丙氨酸作为疫苗佐剂的应用 - Google Patents
丙氨酸作为疫苗佐剂的应用 Download PDFInfo
- Publication number
- CN103520717A CN103520717A CN201310395462.3A CN201310395462A CN103520717A CN 103520717 A CN103520717 A CN 103520717A CN 201310395462 A CN201310395462 A CN 201310395462A CN 103520717 A CN103520717 A CN 103520717A
- Authority
- CN
- China
- Prior art keywords
- vaccine
- alanine
- adjuvant
- application
- inactivated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 title claims abstract description 25
- 235000004279 alanine Nutrition 0.000 title claims abstract description 25
- 239000012646 vaccine adjuvant Substances 0.000 title claims abstract description 15
- 229940124931 vaccine adjuvant Drugs 0.000 title claims abstract description 15
- 229960005486 vaccine Drugs 0.000 claims abstract description 43
- 229940031551 inactivated vaccine Drugs 0.000 claims description 10
- 241000607471 Edwardsiella tarda Species 0.000 claims description 6
- 230000002238 attenuated effect Effects 0.000 claims description 6
- 230000009849 deactivation Effects 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 abstract description 3
- 239000000568 immunological adjuvant Substances 0.000 abstract description 3
- 238000010171 animal model Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 230000036039 immunity Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 5
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 241000646933 Edwardsiella tarda EIB202 Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明涉及生物医药领域,具体公开了丙氨酸作为疫苗佐剂的应用。本发明通过在疫苗添加或不添加丙氨酸,发现试验动物在添加丙氨酸后较不添加丙氨酸的死亡率显著减少,说明丙氨酸可提高疫苗的免疫效果,可以作为疫苗的免疫佐剂。
Description
技术领域
本发明涉及生物医药领域,更具体地,涉及丙氨酸作为疫苗佐剂的应用。
背景技术
丙氨酸是构成蛋白质的基本单位,是组成人体蛋白质的21种氨基酸之一。它的分子式是C3H7O2N,具有预防肾结石、协助葡萄糖的代谢,有助缓和低血糖,改善身体能量。
疫苗佐剂是一类同抗原一起或预先注射进机体,能增强机体对该抗原的免疫应答或改变免疫应答类型的物质。目前最经典的疫苗佐剂是弗氏佐剂,但该佐剂主要用于动物实验,但动物多次注射后常会发生佐剂病。因此发现新的安全、有效、不会引起毒副作用的免疫佐剂具有很重要的应用价值。
发明内容
本发明所要解决的技术问题是,为了克服现有技术中疫苗佐剂种类的不足,提供丙氨酸作为疫苗佐剂的应用。
本发明所要解决的上述技术问题通过以下技术方案予以解决:
丙氨酸或其衍生物或其盐在制备疫苗佐剂方面的应用。
作为一种优选方案,所述的疫苗为灭活疫苗、减毒活疫苗或基因重组疫苗。
作为一种最优选方案,所述的疫苗为灭活迟钝爱德华菌疫苗。
丙氨酸在制备疫苗佐剂中的应用。
作为一种优选方案,所述的疫苗为灭活疫苗、减毒活疫苗或基因重组疫苗。
作为一种最优选方案,所述的疫苗为灭活迟钝爱德华菌疫苗。
丙氨酸作为疫苗佐剂在制备疫苗中的应用。
作为一种优选方案,所述的疫苗为灭活疫苗、减毒活疫苗或基因重组疫苗。作为一种最优选方案,所述的疫苗为灭活迟钝爱德华菌疫苗。
作为一种优选的方案,所述的疫苗为注射制剂,丙氨酸在所述注射制剂中的含量为10μmoL~1mol。
佐剂是非特异性免疫增强剂,当与抗原一起注射或预先注入机体时,可增强机体对抗原的免疫应答或改变免疫应答类型。可以作为佐剂的物质,例如弗氏佐剂,对所有疫苗均具有佐剂作用。故丙氨酸作为佐剂同样可用于任何种类疫苗佐剂。
本发明具有如下有益效果:(1)本发明提供了一种新型的疫苗免疫佐剂;(2)本发明所述的免疫佐剂安全、有效、不会引起毒副作用。
具体实施方式
以下结合具体实施例来进一步解释本发明,但实施例对本发明不做任何形式的限定。
实施例1迟钝爱德华菌EIB202菌株的培养和处理
挑取胰蛋白胨大豆肉汤培养基(TSB)平板上的迟钝爱德华菌EIB202单克隆于TSB试管中,30℃培养24h,按照1:100转接于100mL的TSB培养基中扩大培养。当OD600值达到1.0时离心收菌,用生理盐水洗涤两次后,用生理盐水悬浮菌体使OD600为1.0(细菌数约109个菌/毫升),用于实验小鼠的攻毒。
同时另取部分细菌,加入0.1%的甲醛,30℃孵育24小时使细菌灭活。然后用生理盐水洗涤3次后,用生理盐水悬浮使OD600为1.0(约109cfu/mL),再用生理盐水稀释10倍(约108cfu/mL),得灭活菌疫苗,用于实验小鼠的灭活菌免疫。
实施例2小鼠的免疫
90只4周龄昆明鼠(平均体重25g)随机分配成3组:对照组、灭活菌免疫组和灭活菌+丙氨酸免疫组。对照组每只小鼠腹腔注射100μL生理盐水;灭活菌免疫组每只小鼠腹腔注射上述制备好的灭活菌疫苗100μL(约107个细菌);灭活菌+丙氨酸免疫组每只小鼠腹腔注射注射上述制备好的灭活菌疫苗100μL和内含丙氨酸120μmoL的混合物。连续免疫两次,间隔7天。最后1次免疫后7天,采用EIB202攻毒,剂量为3×108CFU/只,观察15天,统计小鼠的死亡情况。根据公式(相对免疫保护率=[1-(免疫对象的死亡率/未免疫对象的死亡率)]×100%)计算相,对免疫保护率。结果见表1。
表1小鼠的免疫效果
RPS为相对保护率,1是与与生理盐水对照组相比;2是与灭活疫苗免疫组相比;*P<0.05,**P<0.01。
此结果表明,灭活疫苗免疫动物后,与生理盐水对照组相比,免疫效果有显著性提高。而灭活疫苗同时添加丙氨酸后,比单纯使用灭活疫苗的保护率提高了38.9%。此结果说明,丙氨酸能够提高灭活菌疫苗的保护效率。
Claims (10)
1.丙氨酸或其衍生物或其盐在制备疫苗佐剂方面的应用。
2.根据权利要求1所述的应用,其特征在于,所述的疫苗为灭活疫苗、减毒活疫苗或基因重组疫苗。
3.根据权利要求1所述的应用,其特征在于,所述的疫苗为灭活迟钝爱德华菌疫苗。
4.丙氨酸在制备疫苗佐剂中的应用。
5.根据权利要求4所述的应用,其特征在于,所述的疫苗为灭活疫苗、减毒活疫苗或基因重组疫苗。
6.根据权利要求4所述的应用,其特征在于,所述的疫苗为灭活迟钝爱德华菌疫苗。
7.丙氨酸作为疫苗佐剂在制备疫苗中的应用。
8.根据权利要求7所述的应用,其特征在于,所述的疫苗为灭活疫苗、减毒活疫苗或基因重组疫苗。
9.根据权利要求7所述的应用,其特征在于,所述的疫苗为灭活迟钝爱德华菌疫苗。
10.根据权利要求7所述的应用,其特征在于,所述的疫苗为注射制剂,丙氨酸在所述注射制剂中的浓度为10μmoL~1mol。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310395462.3A CN103520717B (zh) | 2013-09-02 | 2013-09-02 | 丙氨酸作为疫苗佐剂的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310395462.3A CN103520717B (zh) | 2013-09-02 | 2013-09-02 | 丙氨酸作为疫苗佐剂的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103520717A true CN103520717A (zh) | 2014-01-22 |
CN103520717B CN103520717B (zh) | 2015-11-18 |
Family
ID=49923302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310395462.3A Expired - Fee Related CN103520717B (zh) | 2013-09-02 | 2013-09-02 | 丙氨酸作为疫苗佐剂的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103520717B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109568575A (zh) * | 2018-12-02 | 2019-04-05 | 河南师范大学 | 一种增强嗜水气单胞菌OmpA疫苗接种效果的小分子代谢物佐剂及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955088A (en) * | 1992-02-03 | 1999-09-21 | Cedars-Sinai Medical Center | Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins |
CN1889976A (zh) * | 2003-10-30 | 2007-01-03 | 卢斯根有限责任公司 | 抗疱疹药物组合物、生产基于其的剂型的方法及其使用方法 |
WO2008024075A1 (en) * | 2006-08-25 | 2008-02-28 | Agency For Science, Technology And Research | Modulators of candida hyphal morphogenesis and uses thereof |
WO2008152654A1 (en) * | 2007-06-11 | 2008-12-18 | Panacea Biotec Limited | Anthrax fusion proteins, compositions and uses thereof |
WO2008151633A2 (en) * | 2007-06-15 | 2008-12-18 | Skau Aps | Vectors for vaccines against lentivirus infections |
-
2013
- 2013-09-02 CN CN201310395462.3A patent/CN103520717B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955088A (en) * | 1992-02-03 | 1999-09-21 | Cedars-Sinai Medical Center | Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins |
CN1889976A (zh) * | 2003-10-30 | 2007-01-03 | 卢斯根有限责任公司 | 抗疱疹药物组合物、生产基于其的剂型的方法及其使用方法 |
WO2008024075A1 (en) * | 2006-08-25 | 2008-02-28 | Agency For Science, Technology And Research | Modulators of candida hyphal morphogenesis and uses thereof |
WO2008152654A1 (en) * | 2007-06-11 | 2008-12-18 | Panacea Biotec Limited | Anthrax fusion proteins, compositions and uses thereof |
WO2008151633A2 (en) * | 2007-06-15 | 2008-12-18 | Skau Aps | Vectors for vaccines against lentivirus infections |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109568575A (zh) * | 2018-12-02 | 2019-04-05 | 河南师范大学 | 一种增强嗜水气单胞菌OmpA疫苗接种效果的小分子代谢物佐剂及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103520717B (zh) | 2015-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101144062B (zh) | 一种干酪乳杆菌菌株及其制品在禽类免疫中的应用 | |
Li et al. | Protective effects of chicken egg yolk antibody (IgY) against experimental Vibrio splendidus infection in the sea cucumber (Apostichopus japonicus) | |
Barbour et al. | A review of approaches targeting the replacement of coccidiostat application in poultry production | |
KR20190080812A (ko) | 백신 제제, 및 어류의 이리도바이러스 감염증 예방 방법 | |
CN104248755A (zh) | 一种副猪嗜血杆菌病疫苗组合物及其制备方法和应用 | |
CN104774791B (zh) | 一种鸡白痢沙门氏菌sp9905及其应用 | |
Denisov et al. | Immunopotentiation of live brucellosis vaccine by adjuvants | |
CN101157907A (zh) | 一种表达猪源支气管败血波氏杆菌fhaB和prn基因片段的重组猪霍乱沙门氏菌株、疫苗及应用 | |
Tahir et al. | Preparation and comparative evaluation of different adjuvanted toxoid vaccines against enterotoxaemia. | |
CN103520717B (zh) | 丙氨酸作为疫苗佐剂的应用 | |
Han et al. | Antimicrobial activity of honey bee venom against select infectious fish pathogens | |
CN108685933B (zh) | 改善猪免疫抑制状态的中药成分方剂及其制备方法和应用 | |
CN102617732A (zh) | 一种新型卵黄抗体及其制备方法 | |
JP6712760B2 (ja) | サルモネラワクチン | |
JP2007238505A (ja) | 魚用ワクチン、その製造方法、および魚類感染症の予防方法 | |
CN105861407A (zh) | 猪链球菌2型溶血素溶血活性基因突变株及其疫苗制备和应用 | |
CN102973730B (zh) | 一种具有清热解毒、抗病毒、提高机体免疫力的兽用中药及其制备方法 | |
CN102352338A (zh) | 一种布鲁氏菌菌壳及其制备方法和应用 | |
CN106995489B (zh) | 一种猪链球菌截短蛋白Sao及应用 | |
CN104248761A (zh) | 一种疫苗组合物及其制备方法和应用 | |
Guo et al. | The efficacy of inactivated photobacterium damselae subsp. piscicida combined with levan/alum as vaccine against photobacteriosis in Cobia, Rachycentron canadum | |
CN102940875B (zh) | Paa蛋白及由其制备的抗体与应用 | |
CN103330935A (zh) | 果糖作为疫苗佐剂的应用 | |
Allan et al. | Innate immune cocktail partially protects broilers against cellulitis and septicemia | |
JP7281208B2 (ja) | SseJタンパク質を用いたサルモネラワクチン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151118 Termination date: 20210902 |